questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Métalloprotéines
Protéines de liaison au fer
Protéines à fer non hème
Lipoxygénases
Arachidonate lipoxygenases
Arachidonate lipoxygenases : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Arachidonate lipoxygenases : Questions médicales les plus fréquentes",
"headline": "Arachidonate lipoxygenases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Arachidonate lipoxygenases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-15",
"dateModified": "2025-04-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Arachidonate lipoxygenases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Lipoxygénases",
"url": "https://questionsmedicales.fr/mesh/D058945",
"about": {
"@type": "MedicalCondition",
"name": "Lipoxygénases",
"code": {
"@type": "MedicalCode",
"code": "D058945",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.556.579.374.568"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Arachidonate 5-lipoxygenase",
"alternateName": "Arachidonate 5-Lipoxygenase",
"url": "https://questionsmedicales.fr/mesh/D001094",
"about": {
"@type": "MedicalCondition",
"name": "Arachidonate 5-lipoxygenase",
"code": {
"@type": "MedicalCode",
"code": "D001094",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.556.579.374.568.500.020"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Arachidonate 12-lipoxygenase",
"alternateName": "Arachidonate 12-Lipoxygenase",
"url": "https://questionsmedicales.fr/mesh/D001092",
"about": {
"@type": "MedicalCondition",
"name": "Arachidonate 12-lipoxygenase",
"code": {
"@type": "MedicalCode",
"code": "D001092",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.556.579.374.568.500.025"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Arachidonate 15-lipoxygenase",
"alternateName": "Arachidonate 15-Lipoxygenase",
"url": "https://questionsmedicales.fr/mesh/D001093",
"about": {
"@type": "MedicalCondition",
"name": "Arachidonate 15-lipoxygenase",
"code": {
"@type": "MedicalCode",
"code": "D001093",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.556.579.374.568.500.030"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Arachidonate lipoxygenases",
"alternateName": "Arachidonate Lipoxygenases",
"code": {
"@type": "MedicalCode",
"code": "D001091",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Hartmut Kuhn",
"url": "https://questionsmedicales.fr/author/Hartmut%20Kuhn",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, D-10117 Berlin, Germany."
}
},
{
"@type": "Person",
"name": "Dagmar Heydeck",
"url": "https://questionsmedicales.fr/author/Dagmar%20Heydeck",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany."
}
},
{
"@type": "Person",
"name": "Deok-Kun Oh",
"url": "https://questionsmedicales.fr/author/Deok-Kun%20Oh",
"affiliation": {
"@type": "Organization",
"name": "Department of Bioscience and Biotechnology, Konkuk University, Seoul, 05029, Republic of Korea. deokkun@konkuk.ac.kr."
}
},
{
"@type": "Person",
"name": "Sabine Stehling",
"url": "https://questionsmedicales.fr/author/Sabine%20Stehling",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, D-10117 Berlin, Germany."
}
},
{
"@type": "Person",
"name": "Michael Rothe",
"url": "https://questionsmedicales.fr/author/Michael%20Rothe",
"affiliation": {
"@type": "Organization",
"name": "Lipidomix GmbH, Robert-Rössle-Straße 10, 13125, Berlin, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Driving more WHO-recommended vaccines in the National Immunization Program: Issues and challenges in China.",
"datePublished": "2023-04-26",
"url": "https://questionsmedicales.fr/article/37099400",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/21645515.2023.2194190"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differential coverage for vaccines in the expanded program on immunization (EPI) among children in rural Pakistan.",
"datePublished": "2023-03-16",
"url": "https://questionsmedicales.fr/article/36933984",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.vaccine.2023.03.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.",
"datePublished": "2022-06-15",
"url": "https://questionsmedicales.fr/article/35703731",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/21645515.2022.2079305"
}
},
{
"@type": "ScholarlyArticle",
"name": "The faces behind vaccination: unpacking the attitudes, knowledge, and practices of staff of Cameroon's Expanded program on Immunization.",
"datePublished": "2023-11-13",
"url": "https://questionsmedicales.fr/article/37957695",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12960-023-00869-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Analyzing the usage of theories of change for routine immunization programs -- a review of impact evaluations from LMICs.",
"datePublished": "2024-09-09",
"url": "https://questionsmedicales.fr/article/39252041",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s41043-024-00615-2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Métalloprotéines",
"item": "https://questionsmedicales.fr/mesh/D008667"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines de liaison au fer",
"item": "https://questionsmedicales.fr/mesh/D033862"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines à fer non hème",
"item": "https://questionsmedicales.fr/mesh/D019159"
},
{
"@type": "ListItem",
"position": 7,
"name": "Lipoxygénases",
"item": "https://questionsmedicales.fr/mesh/D058945"
},
{
"@type": "ListItem",
"position": 8,
"name": "Arachidonate lipoxygenases",
"item": "https://questionsmedicales.fr/mesh/D001091"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Arachidonate lipoxygenases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Arachidonate lipoxygenases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Arachidonate lipoxygenases",
"description": "Comment diagnostiquer une dysfonction des lipoxygénases ?\nQuels tests sont utilisés pour évaluer l'activité des lipoxygénases ?\nLes tests génétiques sont-ils utiles pour les lipoxygénases ?\nQuels symptômes peuvent indiquer un problème avec les lipoxygénases ?\nPeut-on mesurer les niveaux de lipoxygénases dans le sang ?",
"url": "https://questionsmedicales.fr/mesh/D001091?mesh_terms=Immunization+Programs&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Arachidonate lipoxygenases",
"description": "Quels symptômes sont liés à une surproduction de leucotriènes ?\nLes douleurs articulaires peuvent-elles être liées aux lipoxygénases ?\nComment les lipoxygénases affectent-elles la peau ?\nLes allergies peuvent-elles être influencées par les lipoxygénases ?\nQuels signes indiquent une inflammation due aux lipoxygénases ?",
"url": "https://questionsmedicales.fr/mesh/D001091?mesh_terms=Immunization+Programs&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Arachidonate lipoxygenases",
"description": "Comment prévenir les troubles liés aux lipoxygénases ?\nL'exercice physique influence-t-il les lipoxygénases ?\nLe stress a-t-il un impact sur les lipoxygénases ?\nLes habitudes de vie peuvent-elles influencer les lipoxygénases ?\nLes compléments alimentaires sont-ils bénéfiques pour les lipoxygénases ?",
"url": "https://questionsmedicales.fr/mesh/D001091?mesh_terms=Immunization+Programs&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Arachidonate lipoxygenases",
"description": "Quels médicaments ciblent les lipoxygénases ?\nLes corticostéroïdes affectent-ils l'activité des lipoxygénases ?\nComment les acides gras oméga-3 influencent-ils les lipoxygénases ?\nLes traitements naturels peuvent-ils aider avec les lipoxygénases ?\nLa thérapie génique est-elle une option pour les troubles des lipoxygénases ?",
"url": "https://questionsmedicales.fr/mesh/D001091?mesh_terms=Immunization+Programs&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Arachidonate lipoxygenases",
"description": "Quelles complications peuvent survenir avec une dysfonction des lipoxygénases ?\nLes maladies cardiovasculaires sont-elles liées aux lipoxygénases ?\nLes troubles respiratoires peuvent-ils être aggravés par les lipoxygénases ?\nLes troubles métaboliques sont-ils associés aux lipoxygénases ?\nLes cancers peuvent-ils être influencés par les lipoxygénases ?",
"url": "https://questionsmedicales.fr/mesh/D001091?mesh_terms=Immunization+Programs&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Arachidonate lipoxygenases",
"description": "Quels facteurs de risque sont associés aux troubles des lipoxygénases ?\nL'hérédité joue-t-elle un rôle dans les troubles des lipoxygénases ?\nL'exposition à des polluants affecte-t-elle les lipoxygénases ?\nLe vieillissement influence-t-il l'activité des lipoxygénases ?\nLe stress oxydatif est-il un facteur de risque pour les lipoxygénases ?",
"url": "https://questionsmedicales.fr/mesh/D001091?mesh_terms=Immunization+Programs&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des lipoxygénases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests biochimiques et l'analyse des métabolites lipidiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des lipoxygénases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des dosages de leucotriènes dans le sang sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour les lipoxygénases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent identifier des mutations affectant l'activité des lipoxygénases."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec les lipoxygénases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes d'inflammation chronique, comme l'asthme ou l'arthrite, peuvent survenir."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer les niveaux de lipoxygénases dans le sang ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des analyses sanguines peuvent mesurer les niveaux d'enzymes et de métabolites."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une surproduction de leucotriènes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surproduction peut entraîner des symptômes respiratoires, comme la dyspnée et la toux."
}
},
{
"@type": "Question",
"name": "Les douleurs articulaires peuvent-elles être liées aux lipoxygénases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une activité anormale des lipoxygénases peut contribuer à l'inflammation articulaire."
}
},
{
"@type": "Question",
"name": "Comment les lipoxygénases affectent-elles la peau ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent jouer un rôle dans des affections cutanées inflammatoires comme l'eczéma."
}
},
{
"@type": "Question",
"name": "Les allergies peuvent-elles être influencées par les lipoxygénases ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les lipoxygénases sont impliquées dans la réponse allergique et l'inflammation."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une inflammation due aux lipoxygénases ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rougeur, chaleur, gonflement et douleur sont des signes d'inflammation active."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés aux lipoxygénases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et riche en oméga-3 peut aider à prévenir l'inflammation."
}
},
{
"@type": "Question",
"name": "L'exercice physique influence-t-il les lipoxygénases ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut réduire l'inflammation et moduler l'activité des lipoxygénases."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur les lipoxygénases ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut augmenter l'inflammation et affecter l'activité des lipoxygénases."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie peuvent-elles influencer les lipoxygénases ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie saines, comme éviter le tabac, peuvent réduire les risques."
}
},
{
"@type": "Question",
"name": "Les compléments alimentaires sont-ils bénéfiques pour les lipoxygénases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des compléments d'oméga-3 peuvent aider à réguler l'activité des lipoxygénases."
}
},
{
"@type": "Question",
"name": "Quels médicaments ciblent les lipoxygénases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques des lipoxygénases, comme les anti-inflammatoires, sont utilisés."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes affectent-ils l'activité des lipoxygénases ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent réduire l'expression des lipoxygénases et l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment les acides gras oméga-3 influencent-ils les lipoxygénases ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les oméga-3 peuvent moduler l'activité des lipoxygénases et réduire l'inflammation."
}
},
{
"@type": "Question",
"name": "Les traitements naturels peuvent-ils aider avec les lipoxygénases ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales ont des propriétés anti-inflammatoires et peuvent aider."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option pour les troubles des lipoxygénases ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche pour corriger des mutations affectant les lipoxygénases."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dysfonction des lipoxygénases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des maladies inflammatoires chroniques comme l'asthme et l'arthrite."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles liées aux lipoxygénases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une activité anormale des lipoxygénases peut contribuer à l'inflammation cardiovasculaire."
}
},
{
"@type": "Question",
"name": "Les troubles respiratoires peuvent-ils être aggravés par les lipoxygénases ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surproduction de leucotriènes peut aggraver des troubles respiratoires comme l'asthme."
}
},
{
"@type": "Question",
"name": "Les troubles métaboliques sont-ils associés aux lipoxygénases ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des déséquilibres dans l'activité des lipoxygénases peuvent être liés à des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Les cancers peuvent-ils être influencés par les lipoxygénases ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que les lipoxygénases peuvent jouer un rôle dans la progression tumorale."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux troubles des lipoxygénases ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'obésité, le tabagisme et une alimentation riche en graisses saturées augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans les troubles des lipoxygénases ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies inflammatoires peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'exposition à des polluants affecte-t-elle les lipoxygénases ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des polluants environnementaux peut altérer l'activité des lipoxygénases."
}
},
{
"@type": "Question",
"name": "Le vieillissement influence-t-il l'activité des lipoxygénases ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut modifier l'activité des lipoxygénases et augmenter l'inflammation."
}
},
{
"@type": "Question",
"name": "Le stress oxydatif est-il un facteur de risque pour les lipoxygénases ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress oxydatif peut exacerber l'inflammation et affecter l'activité des lipoxygénases."
}
}
]
}
]
}
WHO-recommended vaccines substantially prevent and control vaccine-preventable diseases (VPDs), but their inclusion differs among countries and regions. We reviewed the application for WHO-recommended...
Pakistan has a well-established Expanded Program on Immunization (EPI) however vaccine-preventable diseases still account for high infant and child mortality rates. This study describes the differenti...
From October 2014 to September 2018, we enrolled children younger than 2 years of age from the Matiari Demographic Surveillance System in Sindh, Pakistan. Socio-demographic and vaccination history wer...
Of the 3140 enrolled children, 48.4 % received all EPI recommended vaccines. Only 21.2 % of these were age appropriate. Around 45.4 % of the children were partially vaccinated, and 6.2 % were unvaccin...
Vaccine coverage was low among children in Matiari, Pakistan, and majority received delayed doses. Parents' education status and year of study enrollment was protective against vaccine dropout and del...
In response to the substantial clinical and economic burden of diseases caused by...
A Markov model that simulated the disease processes of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) over a newborn cohort lifetime was used to evaluate the cost-effecti...
Vaccination with PHiD-CV or PCV13 was estimated to avert approximately 700 cases of IPD (200 meningitis, 500 bacteremia), and around 5,000 cases of all-cause pneumonia. However, PHiD-CV vaccination wa...
PCVs are a cost-effective strategy to relieve the burden associated with diseases caused by...
Immunization is regarded as one of the most cost-effective public health interventions in global health. However, its cost-effectiveness depends greatly on the knowledge and skills of vaccinators. Wit...
Through a descriptive cross-sectional design, we used structured questionnaires and observation guides to collect data from vaccination staff in health facilities that were selected by a multistage sa...
Overall, we collected data from Expanded Program on Immunization focal staff in 265 health facilities across 68 health districts. Over half (53%) of the surveyed facilities were found in rural areas. ...
This study suggests marked deficits in immunization knowledge among vaccination staff and exposes common attitudes and practices that could contribute to missed opportunities for vaccination and hinde...
In this article we analyzed the extent of the usage of Theories of Change (TOCs) and causal pathways in the evaluation of immunization programs to identify the challenges to generating evidence on how...
We analyzed the use of the TOC in impact evaluations (IEs) of immunization interventions published after 2010, and its associated articles. The review includes studies from Evidence Gap Map and Yale r...
Our review included 47 large-scale and 45 small-to medium-scale interventions. Of the included studies, 19% used a TOC, 56% described a causal pathway or used a conceptual diagram with varying degrees...
Future implementers and evaluators need to develop clear TOCs that are based on established theory and have clearly articulated the underlying assumptions. Large-scale health system strengthening init...
Rotavirus (RV) vaccination was included in the Finnish National immunization Program (NIP) in 2009. RotaTeq (RV5) has been used exclusively with a national average vaccination coverage rate (VCR) of >...
We first describe the incidence of RVGE, viral gastroenteritis (VGE), and acute gastroenteritis (AGE) for all Finnish children born during 2008-2011. Children were stratified by the year of birth into...
RVGE incidence decreased significantly soon after implementation of RV vaccination in the NIP. In vaccine-eligible cohorts, no clear peak incidence in the youngest age groups could be observed, and no...
Incidence of RVGE has remained low in all age groups during the 10 years following introduction of RV vaccine in the Finnish NIP. Differences in RVGE incidence were observed in regions with high as co...
Measles is a highly transmissible disease that requires high levels of vaccination coverage for control and elimination. Areas that are unable to achieve and maintain high coverage levels are at risk ...
The authors aimed to assess the characteristics and integration of immunization services into the prenatal care provided by maternity care units (MCUs) in Italy....
A cross-sectional nationwide study using a web-based survey was conducted from June to August 2021. The study population consisted of 342 obstetricians/gynecologists (OB/GYNs), members of the Italian ...
Overall, 112 of 342 MCUs completed the survey, for an overall response rate of 32.7%. Almost all MCUs (96.4%) provided vaccine information, but only 22% had an onsite vaccination clinic. Less than hal...
Institutional barriers and lack of certain vaccine-related services offered during prenatal care in Italian MCUs might be responsible for many missed vaccination opportunities. Embedding maternal immu...
Delaying of policies for immunization of aging adults, low vaccine uptake, and the lack of supportive evidence at the national level could diminish the value in health and economics of such programs. ...
The tool was developed in two phases. First, a modified Delphi process was used to construct the tool. The process included a literature review, stakeholder consultations, and a three-round Delphi stu...
The review identified 16 tools and frameworks that formed the first version of our tool with 14 items. Eight experts were involved in the Delphi panel. Through three Delphi rounds, four items were add...
Through a thorough and transparent process, a country score tool was developed helping to identify strengths, weaknesses, and evidential requirements for decision-making and implementation of immuniza...
Since 1994, the U.S. Vaccines for Children (VFC) program has covered the cost of vaccines for children whose families might not otherwise be able to afford vaccines. This report assessed and quantifie...